chr1-236754013-G-A
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PP3_ModerateBS2
The NM_001103.4(ACTN2):c.1906G>A(p.Glu636Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000149 in 1,614,002 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E636G) has been classified as Uncertain significance.
Frequency
Consequence
NM_001103.4 missense
Scores
Clinical Significance
Conservation
Publications
- intrinsic cardiomyopathyInheritance: AD Classification: DEFINITIVE, MODERATE Submitted by: Laboratory for Molecular Medicine, ClinGen
- myopathy, congenital, with structured cores and z-line abnormalitiesInheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
- dilated cardiomyopathy 1AAInheritance: AD Classification: MODERATE, LIMITED Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Ambry Genetics
- familial isolated dilated cardiomyopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- heart conduction diseaseInheritance: AD Classification: LIMITED Submitted by: Genomics England PanelApp
- myopathy, distal, 6, adult-onset, autosomal dominantInheritance: AD, Unknown Classification: LIMITED Submitted by: Broad Center for Mendelian Genomics, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| ACTN2 | NM_001103.4 | c.1906G>A | p.Glu636Lys | missense_variant | Exon 16 of 21 | ENST00000366578.6 | NP_001094.1 | |
| ACTN2 | NM_001278343.2 | c.1906G>A | p.Glu636Lys | missense_variant | Exon 16 of 21 | NP_001265272.1 | ||
| ACTN2 | NR_184402.1 | n.2278G>A | non_coding_transcript_exon_variant | Exon 18 of 23 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152194Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.0000159 AC: 4AN: 251238 AF XY: 0.0000221 show subpopulations
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1461808Hom.: 0 Cov.: 36 AF XY: 0.0000151 AC XY: 11AN XY: 727204 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152194Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74350 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Primary familial hypertrophic cardiomyopathy;C2677338:Dilated cardiomyopathy 1AA Uncertain:1
This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 636 of the ACTN2 protein (p.Glu636Lys). This variant is present in population databases (rs780431842, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ACTN2-related conditions. ClinVar contains an entry for this variant (Variation ID: 222484). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Primary familial hypertrophic cardiomyopathy Uncertain:1
- -
Cardiovascular phenotype Uncertain:1
The p.E636K variant (also known as c.1906G>A), located in coding exon 16 of the ACTN2 gene, results from a G to A substitution at nucleotide position 1906. The glutamic acid at codon 636 is replaced by lysine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at